These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 19857588)

  • 1. Relapse after allogeneic hematopoietic cell therapy.
    van den Brink MR; Porter DL; Giralt S; Lu SX; Jenq RR; Hanash A; Bishop MR
    Biol Blood Marrow Transplant; 2010 Jan; 16(1 Suppl):S138-45. PubMed ID: 19857588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proceedings from the National Cancer Institute's Second International Workshop on the Biology, Prevention, and Treatment of Relapse After Hematopoietic Stem Cell Transplantation: part III. Prevention and treatment of relapse after allogeneic transplantation.
    de Lima M; Porter DL; Battiwalla M; Bishop MR; Giralt SA; Hardy NM; Kröger N; Wayne AS; Schmid C
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):4-13. PubMed ID: 24018392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of Immune Response after Allogeneic Wilms' Tumor 1 Dendritic Cell Vaccination and Donor Lymphocyte Infusion in Patients with Hematologic Malignancies and Post-Transplantation Relapse.
    Shah NN; Loeb DM; Khuu H; Stroncek D; Ariyo T; Raffeld M; Delbrook C; Mackall CL; Wayne AS; Fry TJ
    Biol Blood Marrow Transplant; 2016 Dec; 22(12):2149-2154. PubMed ID: 27634018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science.
    Cairo MS; Jordan CT; Maley CC; Chao C; Melnick A; Armstrong SA; Shlomchik W; Molldrem J; Ferrone S; Mackall C; Zitvogel L; Bishop MR; Giralt SA; June CH
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):709-28. PubMed ID: 20227509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction.
    Miller JS; Warren EH; van den Brink MR; Ritz J; Shlomchik WD; Murphy WJ; Barrett AJ; Kolb HJ; Giralt S; Bishop MR; Blazar BR; Falkenburg JH
    Biol Blood Marrow Transplant; 2010 May; 16(5):565-86. PubMed ID: 20152921
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
    Alyea EP; DeAngelo DJ; Moldrem J; Pagel JM; Przepiorka D; Sadelin M; Young JW; Giralt S; Bishop M; Riddell S
    Biol Blood Marrow Transplant; 2010 Aug; 16(8):1037-69. PubMed ID: 20580849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation.
    Pavletic SZ; Kumar S; Mohty M; de Lima M; Foran JM; Pasquini M; Zhang MJ; Giralt S; Bishop MR; Weisdorf D
    Biol Blood Marrow Transplant; 2010 Jul; 16(7):871-90. PubMed ID: 20399876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor lymphocyte infusions for relapse after allogeneic transplantation: when, if and for whom?
    Chang YJ; Huang XJ
    Blood Rev; 2013 Jan; 27(1):55-62. PubMed ID: 23261066
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allogeneic cell therapy for patients who relapse after autologous stem cell transplantation.
    Porter DL; Luger SM; Duffy KM; Stadtmauer EA; Laport G; Schuster SJ; Orloff G; Tsai D; McDaid K; Kathakali A; Leonard DG; Antin JH
    Biol Blood Marrow Transplant; 2001; 7(4):230-8. PubMed ID: 11349810
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New strategies of DLI in the management of relapse of hematological malignancies after allogeneic hematopoietic SCT.
    Chang X; Zang X; Xia CQ
    Bone Marrow Transplant; 2016 Mar; 51(3):324-32. PubMed ID: 26595077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Donor lymphocyte infusion: the use of alloreactive and tumor-reactive lymphocytes for immunotherapy of malignant and nonmalignant diseases in conjunction with allogeneic stem cell transplantation.
    Slavin S; Morecki S; Weiss L; Or R
    J Hematother Stem Cell Res; 2002 Apr; 11(2):265-76. PubMed ID: 11983098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome and long-term follow-up of alloreactive donor lymphocyte infusions given for relapse after myeloablative allogeneic hematopoietic stem cell transplantations (HSCT).
    Michallet AS; Nicolini F; Fürst S; Le QH; Dubois V; Hayette S; Bourgeot JP; Tremisi JP; Thomas X; Gebuhrer L; Michallet M
    Bone Marrow Transplant; 2005 Mar; 35(6):601-8. PubMed ID: 15756285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Donor lymphocyte infusion following allogeneic hematopoietic stem cell transplantation.
    Roddie C; Peggs KS
    Expert Opin Biol Ther; 2011 Apr; 11(4):473-87. PubMed ID: 21269237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of Low Donor Chimerism after Hematopoietic Cell Transplantation Using Pentostatin and Donor Lymphocyte Infusion: A Prospective Phase II Multicenter Trial.
    Bar M; Flowers MED; Storer BE; Chauncey TR; Pulsipher MA; Thakar MS; Bethge W; Storb R; Maloney DG; Sandmaier BM
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):308-313. PubMed ID: 29032276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD.
    He F; Warlick E; Miller JS; MacMillan M; Verneris MR; Cao Q; Weisdorf D
    Bone Marrow Transplant; 2016 Aug; 51(8):1107-12. PubMed ID: 27064686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
    Feinstein L; Sandmaier B; Maloney D; McSweeney PA; Maris M; Flowers C; Radich J; Little MT; Nash RA; Chauncey T; Woolfrey A; Georges G; Kiem HP; Zaucha JM; Blume KG; Shizuru J; Niederwieser D; Storb R
    Ann N Y Acad Sci; 2001 Jun; 938():328-37; discussion 337-9. PubMed ID: 11458521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned-alemtuzumab allogeneic haematopoietic stem cell transplantation for patients with mature lymphoid malignancies.
    Brierley CK; Jones FM; Hanlon K; Peniket AJ; Hatton C; Collins GP; Schuh A; Medd P; Clark A; Ward J; Chaganti S; Malladi R; Parker A; Craddock C; Danby R; Rocha V
    Br J Haematol; 2019 Feb; 184(4):547-557. PubMed ID: 30467838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.
    Rizzieri DA; Dev P; Long GD; Gasparetto C; Sullivan KM; Horwitz M; Chute J; Chao NJ
    Bone Marrow Transplant; 2009 Feb; 43(4):327-33. PubMed ID: 18850014
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.